Intravacc and Therapyx jointly develop the world’s first prophylactic gonorrhea vaccine

Intravacc and Therapyx jointly develop the world’s first prophylactic gonorrhea vaccine Bilthoven, The Netherlands, 25 August 2020 – Intravacc, a global leader in translational research and development of viral and bacterial vaccines, has partnered with American, Buffalo, NY, based Therapyx, to further develop and optimize the world’s first prophylactic vaccine against gonorrhea, NGoXIM. For this…